Author Archives: Jan Paschal

Rezera Inc. (RZRA Proposed), a Boston biotech planning a Phase 3 trial in 2027 of its leading drug candidate to treat peripheral artery disease (PAD), unveiled the terms for its $200 million IPO early today – Thursday, Nov. 5, 2026 – in an S-1/A filing. Rezera is offering 16.67 million shares at a price range […]

The IPO market is in slow-mo mode as November gets under way. No IPOs are scheduled to price this week. That’s not surprising, considering the U.S. stock market’s plunge on Friday,Oct. 30 – marking the Nasdaq’s worst month since March 2025 – and the mid-term U.S. elections tomorrow – on Tuesday, Nov. 3, 2026. The […]

OPay Ltd. (OPAY), the Nigerian FinTech app, has postponed its IPO indefinitely after the stock did not start trading today, as expected, according to Street sources familiar with the situation, IPOScoop has learned. Clients of a major firm have been notified that it was withdrawing from the IPO. It’s highly unusual for an IPO to […]

Aspen Neuroscience (ASPE), a biotech developing a stem cell therapy to treat patients with Parkinson’s Disease, priced its IPO at $15.00 – the low end of its range – and sold 9.375 million shares – the number in the prospectus – to raise $140.63 million on Thursday night, Oct. 29, 2026. The San Diego-based biotech’s […]

SoftBank-backed OPay Ltd  (OPAY), the parent of Nigeria’s No. 1 digital banking platform, priced its IPO at $19.00 – the low end of its range – and sold 16 million American Depositary Shares (ADS) to raise $304 million on Thursday night, Oct. 29, 2026. Each ADS represents 10 ordinary shares. Fast forward to Friday afternoon: […]

Bambusa Therapeutics (BBTX) upsized its IPO at pricing to 10.55 million shares – up from 9.38 million shares – and priced the IPO at $16.00 – the mid-point of its range – to raise $168.8 million on Thursday night, Oct. 29, 2026. The Boston biotech’s stock slid in its NASDAQ debut – opening at $14.88 […]

BHAV Acquisition Corp. II (BHAIU) raised $100 million tonight – becoming the second SPAC IPO in the $100 million club to get priced this week. Piscataway, N.J.-based BHAV Acquisition II priced 10 million units at $10.00 each to raise $100 million on Wednesday night, Oct. 28, 2026, according to its SEC filing and the company’s […]

Anthropic (ANT  Proposed) pulled back the curtain on  its IPO by filing its long-awaited S-1 this morning – Monday, Oct. 26, 2026. The San Francisco-based AI company, known for Claude, did not disclose the terms for its IPO in its S-1 filing. The IPO pros expect that Anthropic’s IPO could raise about $75 billion – […]

Aspen Neuroscience, Inc. (ASPE Proposed), a Phase 1/2a biotech targeting Parkinson’s Disease, unveiled the terms for its $150 million IPO early today – Monday, Oct. 26, 2026. The San Diego-based biotech is offering 9.38 million shares at a price range of $15.00 to $17.00 to raise $150 million, if priced at the $16.00 mid-point of […]

Bambusa Therapeutics (BBTX Proposed), a clinical biotech developing drugs to treat atopic dermatitis (“AD”) and COPD, set the terms and launched its $150 million IPO early today – Monday, Oct. 26, 2026 – with plans to price the deal this week. Bambusa Therapeutics, Inc. is offering 9.38 million shares at a price range of $15.00 […]